Piper Jaffray analyst Sarah James raised her price target for Henry Schein to $96 after hosting the company's management at her firm's healthcare conference. Management was bullish on the near-term outlook heading into Q4 and 2019, with increased confidence in North America consumable and equipment sales trends, James tells investors in a research note. She adds that management reiterated their long-term earnings growth targets of high-single-digit to low-double-digit. James believes this could prove conservative in 2019 and keeps an Overweight rating on Henry Schein.